Hylio, based just south of Houston, is setting out to bring the agriculture industry into the 21st century. Photo courtesy of Hylio

Renowned American inventor Thomas Edison once said, "There's a way to do it better, find it."

That timeless adage has been the spark that has ignited countless technological advances over the years and Hylio is no different, applying it to its own mission to disrupt the agricultural technology space.

With rampant systemic inefficiencies with current crop spraying solutions negatively affecting farm economics, Hylio developed its AgroDrone, a precision crop spraying drone system that is revolutionizing ag-tech.

"Our company started about five years ago, when we were delivering in Central America and noticed the way people were doing spraying was extremely inefficient," says Arthur Erickson, CEO and co-founder of Hylio. "They were doing it either by hand or by plane or helicopter. If you are doing it by hand, you are doing it extremely slow and very inaccurate. If you're doing it by plane or helicopter, you're doing it faster, but you're extremely inaccurate."

In most cases, when farmers use traditional crop spraying methods such as helicopter or plane, up 90 percent of the fertilizer or pesticides miss their intended targets or float away.

However, AgroDrone, which was recently accepted into the Capital Factory accelerator, provides for a very precise method of applying those chemicals with its intuitive planning system, which monitors and controls the spray volumes using pre-existing map files or polygons.

"For the past year, we've been our own first customer," says Erickson. "We've used the technology in El Salvador, Honduras and Guatemala on 40,000 acres. We learned the product and what made it more efficient by using it in the field 10 hours a day. We built this from the ground up using it as a farmer would. We worked out all the bugs, optimized it and made it reliable, so when farmers are out there in the mud or in the rain, it still works."

The drone's flight software allows it to be completely turnkey. The electron-based application can be run on any cross platform and gives pilots control over the drone at all times.

Additionally, the redundant critical flight system ensures stable flight.

"Our software was made completely in house," says Erickson. "Like a Google map interface, you can set up your own pre-loaded missions, in different polygon shapes, draw them yourself or import polygon files and generate missions for the drone to fly."

Because of the radar altimeters fitted on the drones, farmers are able to reduce the amount of chemicals they use because the drones maintain optimal height over crops at all times, which minimizes drift and maximizes application quality.

"If you talk to any farmer that has 400 acres of corn, for example, and they want to get it sprayed, it would cost them maybe $400 times 10 for labor times 10 for chemicals, so about $8000," says Erickson. "The problem is they're providing a brute force solution to a problem that is very simple to solve with a drone.

"If they've got weeds on their 400 acres, and the weeds are only on one or two acres, little spots in the field, they just want to eliminate those spots, so they don't need to pay someone to spray their entire field, so they're saving the chemical cost per acre is $10 bucks. So if they run our drone for 10 minutes, they're literally saving $7,000 or more."

The innovators behind Hylio started the company because they were passionate about drones, but saw that the crop spraying system for farmers was broken and inefficient, so they sought to make the process better and more sustainable.

"Farmers are responsible for how we eat, how everyone eats," says Erickson. "The current technologies used in agriculture is outdated and not very cost effective. We looked at the farm economics and wanted to help develop viable solutions. Every farmer has to battle weeds; it is universal. All crop and weeds are different, but it is the same concept. The more you control the weeds, the more money you make at the end of the year. A farmer could lose 20 percent or more of their crops if they do not control their weeds properly. Despite the inefficiencies and razor thin margins, farmers still use helicopters and planes because they have to kill those weeds.

"There's a better way to do it with drones and it comes at a fraction of the price."

The AgroDrone starts at $19,300 and is delivered to the farmer fully tested and assembled. The package includes four pairs of 30,000 mAh 22V LiPo batteries, charging equipment, one handheld GPS tracker unit and access to the Hylio AgroSol Mission Control Software.

The software, which was designed by farmers for farmers, requires a recurring monthly fee that ranges from $100 to $500 depending on the level.

Hylio also provides the central device that can control multiple drones at the same time and service hundreds of acres per day.

"The people that are doing the weed control spraying for farmers literally won't come out because it's not worth their time to just come out and spray one or two acres," says Erickson. "So even if a farmer has a problem that they know is only on one or two acres, they have to spray the whole thing, because they market will only allow people to spray the entire amount. They cannot come out and afford to spray one or two acres. However, if you buy a drone, you can do it yourself with the click of a button. Farmers are saving literally $10,000 per application depending on how big their crop is."

According to the US Department of Agriculture, American farmers received $11.5 billion in subsidies in 2017. That number will be drastically higher in 2019 to offset the market losses farmers will see due to President Donald Trump's trade war with China.

With profits in continual decline, Hylio's mission to improve margins for farmers continues.

"Farming is heavily subsidized now," says Erickson. "None of them are making money, so they desperately need something to increase their bottom lines. We are here to make farmers' lives better and help them feed us better. It's a win win."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.